Similarly, we analyzed variant rs804271, previously associated with increased breast cancer risk in BRCA2 mutation carriers (Osorio et al., 2014), which is located within the promoter region of the glycosylase gene NEIL2. The modifier effect of this variant may be due to its negative impact on the performance of the NEIL2 enzyme, leading to an accumulation of oxidative lesions at telomeres (Benítez‐Buelga et al., 2017). This evidence concerns the gene NEIL2 and breast cancer.